Natco Pharma Limited

Natco Pharma Q3FY26 Results: PAT at ₹1,513 Mn, EBITDA at ₹2,168 Mn

Natco Pharma reported Q3FY26 PAT of ₹1,513 Mn and 9MFY26 PAT of ₹11,495 Mn. Q3FY26 EBITDA was ₹2,168 Mn (30.7% margin). Total revenue stood at ₹7,054 Mn. The company acquired a 35.75% stake in Adcock Ingram Holdings Limited and launched Risdiplam in India. An earnings call is scheduled for February 12, 2026.

Natco Pharma declares interim dividend, reappoints key management

Natco Pharma declared a third interim dividend of ₹1.50 per share, with a record date of February 18, 2026. Key management, including the Chairman & MD and Vice Chairman & CEO, were re-appointed for one year from April 1, 2026. The company reported Q3FY26 consolidated revenue of ₹705.4 crore and net profit of ₹151.3 crore.

Natco Pharma declares ₹1.50 interim dividend, re-appoints key management

Natco Pharma declared a third interim dividend of ₹1.50 per share for FY26. The Board re-appointed Chairman & MD, Vice Chairman & CEO, and other key directors for one year from April 1, 2026. Amit Parekh appointed as CFO. Consolidated revenue was ₹705.4 crore, net profit ₹151.3 crore for Q3FY26.

Natco Pharma Receives Tentative US FDA Approval for Erdafitinib Tablets

Natco Pharma received tentative U.S. FDA approval for Erdafitinib tablets (generic of Balversa®). The drug is for advanced urothelial carcinoma. Erdafitinib had U.S. sales of approximately USD 60 million for the 12 months ending Sep '25.

Natco Pharma Receives Tentative Approval for Erdafitinib Tablets

Natco Pharma received tentative FDA approval for its generic Erdafitinib tablets. The drug, a generic of Balversa®, had U.S. sales of approximately USD 60 million for the 12 months ending September 2025. This marks a significant step in expanding Natco's oncology portfolio in the U.S. market.

Natco Pharma to host Q3FY26 Earnings Call on Feb 12, 2026

Natco Pharma will hold an earnings call on February 12, 2026, at 4 PM IST to discuss Q3FY26 results. Vice-chairman Rajeev Nannapaneni and EVP Rajesh Chebiyam will participate. The call is organized by Batlivala & Karani Securities.

Natco Pharma Acquires Remaining 49% Stake in Indonesian Subsidiary for ₹7.7 Crore

Natco Pharma's subsidiary acquired the remaining 49% stake in PT NATCO Lotus Farma for ₹7.7 crore. This brings Natco's total ownership in the Indonesian pharmaceutical subsidiary to 100%. The acquisition was completed via cash consideration.

Natco Pharma clarifies ongoing litigation, no material financial impact yet

Natco Pharma Limited has clarified that an ongoing litigation is continuing, with the outcome awaiting. The company stated there is no material financial impact from the litigation or the related news article as of now. Natco Pharma confirmed adherence to SEBI regulations for disclosures.

Natco Pharma Files SEBI Compliance Certificate for Q3 FY26

Natco Pharma Limited submitted a certificate under SEBI regulations for the quarter ended December 31, 2025. This filing confirms the proper processing of dematerialized securities and updates to depositories' records.

Natco Pharma Releases Sustainability Report 2024-25

Natco Pharma released its Sustainability Report for FY24-25, themed 'Impacting Lives, Sustaining Communities.' The report details ESG performance, including 25% renewable energy usage and 53% water recycling. Key targets include 35% renewable energy by 2035 and carbon neutrality by 2050. R&D spend was ₹3,733 million.

Natco Pharma: Trading Window Closed Jan 1, 2026, Pending Q3 FY26 Results

Natco Pharma Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ending December 31, 2025. The date of the board meeting for results declaration will be intimated later.

Natco Pharma appoints Amit Parekh as Executive VP - Finance & Accounts

Natco Pharma appoints Amit Parekh as Executive VP - Finance & Accounts, effective December 2, 2025, as part of succession planning, succeeding the current CFO in February 2026.

ICRA reaffirms Natco Pharma's credit ratings

ICRA reaffirms Natco Pharma's credit ratings with a stable outlook, citing a healthy financial profile and strong R&D capabilities. Key ratings include [ICRA]AA (Stable)/[ICRA]A1+ for various facilities and commercial paper.

NATCOPHARM Announces Conclusion of US FDA Inspection at Chennai API Unit

NATCO Pharma concludes US FDA inspection at its Chennai API unit with seven observations, which the company believes are procedural and will address comprehensively.

Natco Pharma Q2 FY26 Earnings Call Transcript

Natco Pharma releases Q2 FY26 earnings call transcript, reporting consolidated revenue of ₹1,463 crore and net profit of ₹517.9 crore. Interim dividend declared at ₹1.5 per share.

Natco Pharma publishes Q2 FY26 results and notice for 2nd interim dividend record date

Natco Pharma published unaudited Q2 FY26 financial results and announced the record date for its 2nd interim dividend through newspaper publications on November 15, 2025.

Natco Pharma releases Q2 FY26 earnings call audio recording

Natco Pharma uploaded the audio recording of its Q2 FY26 earnings conference call, held on November 14, 2025, for the quarter ended September 30, 2025, to its website.

Natco Pharma Reports Strong Q2 FY26 Financials, ₹1,463 Cr Revenue & Strategic Investments

Natco Pharma announced strong Q2 FY26 results with ₹1,463 crore revenue and ₹517.9 crore PAT. The company highlighted robust product pipelines and strategic investments in cell & gene therapy. An earnings call is scheduled for November 14, 2025.

Natco Pharma declares ₹1.50 interim dividend for FY25-26; Record Date: Nov 20, 2025

Natco Pharma declared an interim dividend of ₹1.50 per share for FY25-26. The record date is November 20, 2025, with payments starting November 28, 2025.

Natco Pharma Board Approves Q2 Results, Declares Interim Dividend, and Progresses Demerger

Natco Pharma announced Q2/H1 FY26 results, declared ₹1.50 interim dividend with November 20 record date, and approved subsidiary incorporation for Crop Health Sciences demerger.

NATCO Pharma completes Adcock Ingram delisting, expands African presence with US$226mn acquisition

NATCO Pharma completed the acquisition and delisting of South African firm Adcock Ingram for US$ 226 million (₹1880.89 crore), securing a 35.75% stake and expanding its global footprint in Africa.

Natco Pharma Revised Invite for Q2FY26 Earnings Call on 14 Nov 2025

Natco Pharma to host Q2FY26 earnings call on November 14, 2025, at 16:00 PM IST to discuss financial results for quarter and half year ended September 30, 2025.

Natco Pharma to host Q2FY26 Earnings Call on November 14, 2025

Natco Pharma announced an earnings call for Q2FY26 financial results on November 14, 2025, to discuss performance for the quarter and half year ended September 30, 2025.

NATCO Pharma launches Everolimus 1mg tablets, a generic version of Zortress®, in the U.S. market

NATCO Pharma has launched Everolimus 1mg tablets, a generic version of Novartis's Zortress®, in the U.S. market through its partner Breckenridge Pharmaceutical, Inc. for organ transplant patients.

Natco Pharma Receives Favorable Ruling in Risdiplam Lawsuit

Supreme Court dismisses Roche's petition against Natco Pharma in Risdiplam suit, upholding prior rulings. This decision allows the suit to proceed to trial, potentially benefiting SMA patients in India.

Natco Pharma Updates on Proposed Acquisition of Adcock Ingram Shares

Natco Pharma's Scheme Resolution for acquiring Adcock Ingram shares passed on Oct 9, 2025. Delisting details to follow.

Submission of Certificate under SEBI (Depositories and Participants) Regulations, 2018

Natco Pharma submitted the Regulation 74(5) certificate for the quarter ended September 30, 2025, confirming proper dematerialization of securities and updating depository records within 15 days.

NATCO Pharma wins Risdiplam patent case, to launch generic drug immediately at ₹15,900 MRP

NATCO Pharma won a patent case against Roche, allowing immediate launch of generic Risdiplam for SMA at ₹15,900, with a patient access program to ensure affordability.

Natco Pharma Appoints Mr. G. Vijay Kiran Kumar as VP - Corporate Quality Assurance (Formulations)

Natco Pharma appointed Mr. G. Vijay Kiran Kumar as Vice President – Corporate Quality Assurance (Formulations) effective 9th October, 2025, bringing over 24 years of pharma experience.

Natco Pharma: Proceedings of 42nd Annual General Meeting

Natco Pharma Board approves in-principle evaluation for Agro business demerger

Natco Pharma's Kothur Unit Receives EIR with VAI Classification from US FDA

Natco Pharma to Acquire Minority Shares in Adcock Ingram for ZAR 4 Billion

Natco Pharma to attend Investec 'Guru Speek series 2.0' virtual investor meeting

Natco Pharma to hold 42nd AGM on September 25, 2025 via Video Conferencing

NATCO launches Bosentan Tablets (generic of Tracleer®) in US with exclusivity

Natco Pharma Reports Q1 FY26 Earnings, Cites Revlimid Pressure and Strategic Investments

Natco Pharma to Host Earnings Call for Q1 FY26 Unaudited Financial Results

Natco Pharma appoints T.C. Mallikarjun as Vice President – QC

Natco Pharma to Acquire 35.75% Stake in Adcock Ingram for ₹2,000 Crore

Natco Pharma's Mekaguda API Plant Receives US FDA Establishment Inspection Report (EIR)

Natco Pharma to host investor call on proposed investment

NATCO Pharma to acquire 35.75% stake in South Africa's Adcock Ingram for ₹2,000 crore